Skip to main content

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3:


1. Purpose:

The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities.

2. Applicability:

ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies.

3. Structure of the CSR:

The guideline outlines a standardized structure for the CSR, which typically includes the following sections:

  • Title Page
  • Table of Contents
  • Summary
  • Introduction
  • Investigational Product Information
  • Investigator's Brochure
  • Trial Objectives and Purpose
  • Trial Design
  • Selection of Patients
  • Treatment of Patients
  • Assessment of Efficacy
  • Assessment of Safety
  • Statistics
  • Discussion
  • Conclusions
  • References
  • Appendices

4. Detailed Content:

ICH E3 provides detailed recommendations for the content of each section, including what information should be included under each heading. This helps ensure that the CSR is comprehensive and covers all relevant aspects of the clinical trial.

5. Summary Sections:

The guideline highlights the importance of summary sections at the beginning of the CSR. These sections provide a concise overview of the trial, its objectives, key findings, and conclusions. They are particularly useful for regulatory authorities and other readers who may need to quickly assess the trial's results.

6. Patient Data Protection:

ICH E3 emphasizes the need to protect patient confidentiality and provides guidance on redacting patient-identifying information from the CSR.

7. Quality Control and Review:

The guideline recommends rigorous quality control processes to ensure the accuracy and reliability of the information presented in the CSR. It also emphasizes the importance of a thorough review process.

8. Regulatory Submissions:

The CSR is a critical component of regulatory submissions, such as New Drug Applications (NDAs) or Marketing Authorization Applications (MAAs). The guideline provides guidance on the submission of CSRs to regulatory authorities.

9. Amendments and Updates:

If amendments or updates to the CSR are necessary, ICH E3 provides recommendations on how to handle and document these changes.

10. Compliance:

- Compliance with ICH E3 is essential for pharmaceutical companies conducting clinical trials and submitting regulatory applications. It ensures that CSRs meet the standards required by regulatory authorities for the evaluation of investigational drugs.


In summary, ICH E3 provides a standardized framework for the structure and content of clinical study reports (CSRs). Compliance with this guideline helps ensure that CSRs are organized, comprehensive, and clear, making it easier for regulatory authorities to evaluate the safety and efficacy of investigational drugs during the drug development process.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

ICH 5QC Stability testing of biotechnological/biological products (CPMP/ICH/138/95)

ICH Topic Q5C, as outlined in document CPMP/ICH/138/95, addresses the stability testing of biotechnological and biological products. This guideline provides a framework for assessing the stability of these products over time, ensuring that they maintain their quality, safety, and efficacy throughout their shelf life. Below is an elaboration of ICH Q5C: 1. Purpose of ICH Q5C: The primary purpose of ICH Q5C is to establish principles and guidelines for conducting stability testing of biotechnological and biological products. The goal is to provide evidence that these products remain safe and effective during their intended shelf life. 2. Types of Products Covered: ICH Q5C applies to a wide range of biotechnological and biological products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and other biopharmaceuticals. 3. Stability Study Design: The guideline outlines the design of stability studies, including the selection of relevant storage conditions, ti...
Read more